1. Home
  2. PT vs EQ Comparison

PT vs EQ Comparison

Compare PT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PT
  • EQ
  • Stock Information
  • Founded
  • PT 2012
  • EQ 2017
  • Country
  • PT China
  • EQ United States
  • Employees
  • PT N/A
  • EQ N/A
  • Industry
  • PT Computer Software: Programming Data Processing
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • PT Technology
  • EQ Health Care
  • Exchange
  • PT Nasdaq
  • EQ Nasdaq
  • Market Cap
  • PT 15.2M
  • EQ 13.1M
  • IPO Year
  • PT 2018
  • EQ 2018
  • Fundamental
  • Price
  • PT $0.98
  • EQ $1.23
  • Analyst Decision
  • PT
  • EQ Buy
  • Analyst Count
  • PT 0
  • EQ 3
  • Target Price
  • PT N/A
  • EQ $3.00
  • AVG Volume (30 Days)
  • PT 7.9K
  • EQ 21.8M
  • Earning Date
  • PT 08-26-2025
  • EQ 08-14-2025
  • Dividend Yield
  • PT N/A
  • EQ N/A
  • EPS Growth
  • PT N/A
  • EQ N/A
  • EPS
  • PT N/A
  • EQ N/A
  • Revenue
  • PT $4,814,566.00
  • EQ $16,553,000.00
  • Revenue This Year
  • PT N/A
  • EQ N/A
  • Revenue Next Year
  • PT N/A
  • EQ N/A
  • P/E Ratio
  • PT N/A
  • EQ N/A
  • Revenue Growth
  • PT N/A
  • EQ N/A
  • 52 Week Low
  • PT $0.76
  • EQ $0.27
  • 52 Week High
  • PT $1.15
  • EQ $1.50
  • Technical
  • Relative Strength Index (RSI)
  • PT 53.96
  • EQ 77.37
  • Support Level
  • PT $0.88
  • EQ $0.78
  • Resistance Level
  • PT $0.98
  • EQ $1.25
  • Average True Range (ATR)
  • PT 0.05
  • EQ 0.23
  • MACD
  • PT 0.00
  • EQ 0.06
  • Stochastic Oscillator
  • PT 59.58
  • EQ 77.78

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: